Key result
Targeting angiotensinogen emerges as an early intervention strategy to prevent hypertension and cardiovascular disease.
Why the study?
Current hypertension treatment is initiated only after blood pressure exceeds thresholds, leaving many at risk untreated and highlighting the need for earlier, upstream prevention strategies.
Can targeting angiotensinogen safely delay or prevent incident hypertension and cardiovascular disease in selected at-risk populations?
Can targeting angiotensinogen safely delay or prevent incident hypertension and cardiovascular disease in selected at-risk populations?
Answers are grounded in this paper and cite their sources.
Targeting angiotensinogen could provide an upstream, durable strategy to prevent the development of overt hypertension and associated cardiovascular disease in at-risk populations.
Uncontrolled hypertension remains the single greatest contributor to cardiovascular disease morbidity and mortality worldwide. Even modest elevations, so-called “high-normal” BP levels, confer significant risk over the course of a lifetime. However, the current treatment paradigm remains rooted in a threshold-based strategy in which treatment is only initiated after BP exceeds predefined cut-points, leaving many who might benefit over the long term untreated. Shifting the paradigm towards earlier treatment and prevention of overt hypertension would require a target that is upstream, durable, and demonstrably safe for long-term use in lower-risk populations. In this review, we examine the concept that targeting angiotensinogen, the most upstream precursor in the renin–angiotensin–aldosterone system (RAAS), could contribute to an earlier, trajectory-focused strategy for preventing hypertension and cardiovascular disease. We review the rationale for targeting angiotensinogen, summarize the evidence for current agents in development, and propose a research agenda to determine whether this approach can safely delay or prevent incident hypertension in selected at-risk populations.
No takes yet. Share an insight, caveat, or question.
Viera et al. (2026) conducted a review in Hypertension and Cardiovascular Disease. Targeting angiotensinogen was evaluated. Targeting angiotensinogen is proposed as an earlier, trajectory-focused strategy for preventing incident hypertension and cardiovascular disease in at-risk populations.
Synapse has enriched 10 related papers. Consider them for comparative context: